New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
19:16 EDTARNA, CRAY, Z, TRLA, NNA, PHMD, LOGM, VSI, GNC, GSK, LCAV, CLF, A, WTWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Cliffs Natural (CLF), up 6.4% after reporting better-than-expected earnings and announcing it promoted Gary Halverson, formerly its president and COO, to president and CEO... LogMeln (LOGM), up 16%... Cray (CRAY), up 9.7%. ALSO HIGHER: LCA Vision (LCAV), up 29% after announcing an agreement to be acquired by PhotoMedex (PHMD) for $5.37 per share. Shares of PhotoMedex were little changed following the announcement... Arena Pharmaceuticals (ARNA), up 1.8% after the Daily Mail said GlaxoSmithKline (GSK) could be interested in a deal for the company. DOWN AFTER EARNINGS: Weight Watchers (WTW), down 20% after fourth quarter profit missed expectations and the company sharply cut its fiscal 2014 earnings outlook... GNC Holdings (GNC), down 15.7%... Trulia (TRLA), down 15.2%... Agilent (A), down 6%. ALSO LOWER: Vitamin Shoppe (VSI), down 8.5% after its vitamin retailing peer GNC reported disappointing fourth quarter sales and cut its fiscal 2014 outlook... Zillow (Z), down 3% after online real estate peer Trulia's quarterly report disappointed... Navios Maritime Acquisition (NNA), down 8.4% after filing to sell 12M shares of common stock.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 9, 2015
18:31 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for OPDIVO
Subscribe for More Information
15:23 EDTADako announces FDA approval of new lung test for cancer patients
Subscribe for More Information
08:02 EDTLOGMLogMeln acquires LastPass for $110M in cash
LogMeIn announced that it has agreed to acquire LastPass. A high growth business with millions of loyal users and an award winning product line, LastPass will immediately bolster LogMeIn's position in the multi-billion dollar identity and access management market, while accelerating one of the company's key strategic growth initiatives. The deal is expected to close in the coming weeks. Under the terms of the transaction, LogMeIn will pay $110M in cash upon close for all outstanding equity interests in LastPass, with up to an additional $15M in cash payable in contingent payments which are expected to be paid to equity holders and key employees of LastPass upon the achievement of certain milestone and retention targets over the two-year period following the closing of the transaction.
October 8, 2015
07:46 EDTCLFCliffs Natural October volatility elevated on wide price movement
Subscribe for More Information
07:08 EDTGSKCodexis earns $6.5M milestone payment from GlaxoSmithKline
Codexis (CDXS) announced that it successfully completed Wave 2 of the transfer of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK) in Q3 of 2015. Codexis expects to receive a $6.5M payment from GSK for completion of this milestone in Q4. Codexis has received a $6M upfront payment and a $5M Wave 1 technology transfer milestone payment from GSK since announcing the technology collaboration and license agreement with GSK in July 2014. The agreement grants GSK a license to use Codexis' CodeEvolver platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products. The CodeEvolver platform technology has been installed and is operational at a GSK facility in Pennsylvania. Codexis is eligible to receive an additional $7.5M payment from GSK subject to the satisfactory completion of the final CodeEvolver technology transfer milestone. Codexis also has the potential to receive numerous additional contingent milestone payments under the agreement with GSK that range from $5.75M-$38.5M per project based on GSK's successful application of the licensed technology. In addition, Codexis will be eligible to receive royalties based on net sales, if any, of a limited set of products developed by GSK using Codexis' CodeEvolver protein engineering platform technology.
October 6, 2015
16:21 EDTCLFCliffs Natural terminates purchase agreement with Essar Algoma
Subscribe for More Information
13:32 EDTGSKBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
18:56 EDTARNAOn The Fly: After Hours Movers
HIGHER: Regulus Therapeutics (RGLS), up 8.7% after the company announced that it will present new preclinical data on RG-012 for kidney disease... Palatin Technologies (PTN), up 9.6% after director Robert deVeer Jr. buys 10,000 shares of common stock... Arena Pharmaceuticals (ARNA), up 4.7% after CEO Jack Lief announced his retirement and Harry Hixson was named interim CEO... DuPont (DD), up 5.9% after CEO and chair Ellen Kullman retires... Ruckus Wireless (RKUS), up 4.9% after joining the S&P 600... Starz (STRZA), up 10.1% after the LA Times reports that Lionsgate (LGF) is in advanced talks to merge with Starz. DOWN AFTER EARNINGS: Container Store (TCS), down 10.4%. ALSO LOWER: Sarepta Therapeutics (SRPT), down 3.8% after filing to sell $125M of common stock... Haemonetics (HAE), down 12.2% after lowering its fiscal 2016 outlook... Energy XXI (EXXI), down 8.3% after filing a $500M mixed securities shelf... Mallinckrodt (MNK), down 1.6% after announcing that it will provide a business update and financial guidance for the fiscal year ending September 30, 2016, on an investor call on October 6.
16:20 EDTARNAArena Pharmaceuticals CEO Jack Lief retires, Harry Hixson named interim CEO
Subscribe for More Information
10:16 EDTCLFBofa/Merrill global metals/mining analysts hold analyst/industry conference call
U.S. Metals, Mining & Steel Analyst Tanners, European Metals, Mining & Steel Analyst Ekblom, Russian Metals, Mining & Steel Analyst Faritov and LatAm Metals, Mining & Steel Analyst Lofiego, along with Sebastian Lewis, Editorial Director-China of Platts, review market conditions in key regions and discusses recent price moves in iron ore, met coat and steel on an Analyst/Industry conference call to be held on October 8 at 9 am.
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
October 1, 2015
08:04 EDTGSKPfizer completes acquisition of Nimerix, Mencevax from GSK
Pfizer (PFE) announced that it has completed the acquisition of GlaxoSmithKline's (GSK) quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
06:02 EDTZZillow management to meet with JMP Securities
Subscribe for More Information
September 30, 2015
12:41 EDTGSKGlaxoSmithKline exercises option for Liquidia Technologies' inhaled therapeutics
Liquidia Technologies announced that GlaxoSmithKline has exercised its option under a Collaboration and Option Agreement signed in 2012 to exclusively license the right to research, develop, and commercialize inhaled therapeutics derived from the company's proprietary PRINT technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies. According to the agreement signed in June 2012, Liquidia was granted an upfront payment comprised of cash and equity, R&D funding, and potential development milestones and royalties. As a result of the GSK decision to exercise the option, Liquidia will receive an option fee, continued R&D funding, and potential product-based development and regulatory milestone payments. Liquidia has also retained the ability to independently develop an inhaled treatment for a particular disease field.
10:00 EDTCLFBofa/Merrill global metals/mining analysts hold analyst/industry conference call
Subscribe for More Information
September 29, 2015
07:30 EDTCLFCliffs Natural volatility at upper end of 52-week range
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use